ASCO 2023 Annual Meeting

The American Society of Clinical Oncology's (ASOC) 2023 Annual Meeting will be held June 2–6, 2023, both in-person in Chicago, IL, and virtually. Over 40,000 oncology professionals from around the world will attend this prestigious event, which provides updates on new clinical advances in every area of cancer research and strives to advance equitable cancer care through international innovation.

See the full program »

The Mass General Cancer Center will have a strong presence at this event, with dozens of leaders sharing their latest research in abstract presentations, poster sessions, discussions and more.

Friday, June 2, 2023

Phase III NATALEE Trial of Ribociclib + Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2− Early Breast Cancer
2:45 pm: Hall D1
Aditya Bardia, MD, MPH

Association of Tumor-infiltrating Lymphocytes (TILs) With Clinicopathologic Characteristics and Prognosis in Young Women With HR+/HER2- Breast Cancer (BC)
4:09 pm: Hall D1
Jeffrey Peppercorn, MD, MPH

Phase II Trial of Pembrolizumab in Patients With Brain Metastases
4:21 pm: S100a and Livestream
Priscilla K. Brastianos, MD

Belzutifan Treatment for Von Hippel-Lindau (VHL) Disease–associated Central Nervous System (CNS) Hemangioblastomas (HBs) in the Phase 2 LITESPARK-004 Study
5:09 pm: S100a and Livestream
Othon Iliopoulos, MD

New Rules for Overcoming Persistent ITP: Expert Guidance on Later-line Care, the Role of BTKi, and Improving Patient Outcomes
6:30 pm: Grand Ballroom CD
David Kuter, MD, DPhil

Saturday, June 3, 2023

Frequency of Delayed Immune-related Adverse Events (irAEs) in Hospitalized Patients Treated With Immune Checkpoint Inhibitors (ICIs)
8:00 am: Hall A and On Demand
Sienna Durbin, MD; Leyre Zubiri, MD, PhD; Kerry L. Reynolds, MD

BLU-222, an Oral, Potent, and Selective CDK2 Inhibitor, in Patients With Advanced Solid Tumors: Phase 1 Monotherapy Dose Escalation
8:00 am: Hall A and On Demand
Dejan Juric, MD

Phase 1 Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination With Capecitabine (Cape) or Gemcitabine (Gem) in Advanced Solid Tumors
8:00 am: Hall A and On Demand
Dejan Juric, MD

Phase 1/1b Study of SY-5609, a Selective and Potent CDK7 Inhibitor, in Advanced Solid Tumors and in 2L/3L Pancreatic Ductal Adenocarcinoma (PDAC) in Combination With Gemcitabine +/- Nab-Paclitaxel
8:00 am: Hall A and On Demand
Dejan Juric, MD

Clinical Outcomes of Immune Checkpoint Inhibitor Treatment in Patients With Classic Cold Tumors Identified to Have a High Tumor Mutational Burden via ctDNA
8:00 am: Hall A and On Demand
Xin Gao, MD

Abatacept for Immune Checkpoint Inhibitor Associated Myocarditis (ATRIUM): Phase 3, Investigator-initiated, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Patients With Immune Checkpoint Inhibitor Associated Myocarditis
8:00 am: Hall A and On Demand
Kerry L. Reynolds, MD; Meghan Mooradian, MD; Leyre Zubiri, MD, PhD

Phase 2 Study of Batiraxcept (AVB-S6-500, an AXL inhibitor) as Monotherapy, in Combination With Cabozantinib (Cabo), and in Combination With Cabo and Nivolumab (Nivo) in Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
8:00 am: Hall A and On Demand
Xin Gao, MD

A Phase 2, Randomized, Open-label Study Comparing the Effects of Darolutamide Versus Enzalutamide Monotherapy on Serum Testosterone Levels in Patients With Hormone-naive Prostate Cancer: ARAMON Study
8:00 am: Hall A and On Demand
Xin Gao, MD; Matthew Smith, MD, PhD

Discovery of Gene Fusions in Driver-negative NCI-MATCH Screening Samples.
8:00 am: Hall A and On Demand
Stefan T. Kaluziak, PhD

Tolerability and Preliminary Activity of the Potent, Selective, Oral CDK7 inhibitor SY-5609 in Combination With Fulvestrant in Patients With Advanced Hormone Receptor-positive (HR+), HER2- Breast Cancer (BC)
8:00 am: Hall A and On Demand
Dejan Juric, MD

National Survey of Financial Burdens and Experience Among Patients With Cancer Receiving Charitable Co-pay Assistance
1:15 pm: Hall A and On Demand
Jeffrey Peppercorn, MD, MPH; Ryan Nipp, MD, MPH

Association Between Targeted Cancer Drug Net Health Benefit and Uptake, Patient Out-of-Pocket Spending, and Total Spending
1:15 pm: Hall A and On Demand
Kelsey S. Lau-Min, MD, MS

Mortality Among Oncology Patients With Multiple Unplanned Hospital Admissions
1:15 pm: Hall A and On Demand
Thomas J. Roberts, MD, MBA; Jessica McGuire, RN, OCN; Jennifer Temel, MD; Daniel Lage, MD, MSc; Joseph Greer, PhD; Therese Mulvey, MD

Financial Toxicity, Quality of Life, Symptom Burden, and Access to Resources in Early-phase Clinical Trial (EP-CT) Participants
1:15 pm: Hall A and On Demand
Sienna Durbin, MD

Immune Checkpoint Inhibitor (ICI) Therapy in Glioblastoma: Institutional Experience at the Massachusetts General Hospital
1:15 pm: Hall A and On Demand
John Yohan Rhee, MD; Kun Wei Song, MD; Isabel Arrillaga-Romany, MD, PhD; Deborah Forst, MD; Justin Jordan, MD, MPH; Ina Ly, MBBS; Scott Plotkin, MD; Nancy Wang, MD; Michael W. Parsons, PhD; Elizabeth R. Gerstner, MD; Jorg Dietrich, MD, PhD

Belzutifan Treatment of Von Hippel-Lindau (VHL) Related Central Nervous System (CNS) Hemangioblastomas (HBs): A Single Institution Experience
1:15 pm: Hall A and On Demand
Othon Iliopoulos, MD

MTHFR Polymorphisms and Neurotoxicity and Overall Survival After Methotrexate-based Therapy in Primary CNS Lymphoma
1:15 pm: Hall A and On Demand
Tracy Batchelor, MD, MPH; Scott Plotkin, MD; Jorg Dietrich, MD, PhD; Michelle Pisapia, RNMSNP; Priscilla K. Brastianos, MD

Multi-cancer Brain Metastasis Risk Score Development and Validation Using 220,246 Whole Transcriptomes and Machine Learning
1:15 pm: Hall A and On Demand
Priscilla K. Brastianos, MD

Novel Genomic Alterations and Transcriptomic-based Tumor Microenvironment Classification of Sarcoma and Their Impact on Treatment Decision Making
1:15 pm: Hall A and On Demand
Gregory Cote, MD, PhD

Selection Biases in the Systematic Collection of Breast Biobank Specimens
1:15 pm: Hall A and On Demand
Yael Bar, MD, PhD; Steven Isakoff, MD, PhD; Beverly Moy, MD, MPH; Leif Ellisen, MD, PhD; Laura Spring, MD; Constance Lehman, MD, PhD

First-in-Human Phase 1/2a Study of a Potent and Novel CDK2-selective Inhibitor PF-07104091 in Patients (pts) With Advanced Solid Tumors, Enriched for CDK4/6 Inhibitor Resistant HR+/HER2- Breast Cancer
1:15 pm: S100bc and On Demand
Dejan Juric, MD

Survey of Hematology/Oncology Fellowship Program Directors on Equity and Global Health Opportunities for Trainees
2:30 pm
Ayo Samuel Falade, MD

The impact of surgery on patients with VHL-associated tumors: An international patient survey
3:00 pm: E450
Othon Iliopoulos, MD

Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
6:30 pm
David Kuter, MD, DPhil

Sunday, June 4, 2023

A Review of Diversity, Equity, and Inclusion (DEI) Eforts by Medical Oncology Journals
8:00 am: Hall A and On Demand
Inas Abuali, MBCHB; Aparna Parikh, MD

ESR1 Mutational Landscape and Impact of Co-existing Resistance Variants on Clinical Outcomes in Patients With Metastatic Breast Cancer
8:00 am: Hall A and On Demand
Arielle J. Medford, MD; Seth Wander, MD, PhD; Laura Spring, MD; Neelima Vidula, MD; Steven Isakoff, MD, PhD; Beverly Moy, MD, MPH; Leif Ellisen, MD, PhD; Gad Getz, PhD; Aditya Bardia, MD, MPH

Association of Pretreatment Chest CT Abnormalities With Trastuzumab Deruxtecan–associated Pneumonitis
8:00 am: Hall A and On Demand
Rachel Occhiogrosso Abelman, MD, Beverly Moy, MD, MPH; Leif Ellisen, MD, PhD; Aditya Bardia, MD, MPH; Florian Fintelmann, MD; Laura Spring, MD

INAVO121: Phase III Study of Inavolisib (INAVO) + Fulvestrant (FUL) vs. Alpelisib (ALP) + FUL in Patients (pts) With Hormone Receptor-positive, HER2-negative (HR+, HER2–) PIK3CA-mutated (mut) Locally Advanced or Metastatic Breast Cancer (LA/mBC)
8:00 am: Hall A and On Demand
Dejan Juric, MD

Trop-2 mRNA Expression and Association With Clinical Outcomes With Sacituzumab Govitecan (SG) in Patients With HR+/HER2– Metastatic Breast Cancer (mBC): Biomarker Results From the Phase 3 TROPiCS-02 Study
8:00 am: Hall A and On Demand
Aditya Bardia, MD, MPH

Tissue and Plasma-based Mechanisms of Resistance to First-line Osimertinib in EGFR-mutant NSCLC: A Multi-institutional Cohort
8:00 am: Hall A and On Demand
Zofia Piotrowska, MD, MHS

First Results From the RETgistry: A Global Consortium for the Study of Resistance to RET Inhibition in RET-altered Solid Tumors
8:00 am: Hall A and On Demand
Alissa Jamie Cooper, MD

Image-only Deep Learning Risk Model Performance in Patients With Known Germline Mutations
8:00 am: Hall A and On Demand
Faezeh Sodagari, MD

Phase II Study of a PARP Inhibitor in Somatic BRCA1/2 Mutant Metastatic Breast Cancer (MBC)
8:00 am: Hall A and On Demand
Neelima Vidula, MD; Aditya Bardia, MD, MPH

Long-term Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
8:00 am: Hall A and On Demand
Jessica Jiyeong Lin, MD

Oral Elacestrant vs Standard-of-Care in Estrogen Receptor-positive, HER2-negative (ER+/HER2-) Advanced or Metastatic Breast Cancer (mBC) Without Detectable ESR1 Mutation (EMERALD): Subgroup Analysis by Prior Duration of CDK4/6i Plus Endocrine Therapy (ET)
8:00 am: Hall A and On Demand
Aditya Bardia, MD, MPH

A Review of Diversity, Equity, and Inclusion (DEI) Efforts by Medical Oncology Journals
8:00 am: Hall A and On Demand
Inas Abuali, MBCHB; Aparna Parikh, MD

VERITAC-2: A Global, Randomized Phase 3 Study of ARV-471, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER+/human Epidermal Growth Factor Receptor 2 (HER2)- Advanced Breast Cancer
8:00 am: Hall A and On Demand
Seth Wander, MD, PhD; Steven Isakoff, MD, PhD; Beverly Moy, MD, MPH; Leif Ellisen, MD, PhD; Aditya Bardia, MD, MPH; Jennifer Shin, MD

Real-World (RW) Outcomes of Patients (pts) With Advanced Breast Cancer (aBC) With and Without Resistance Alterations (alts) Detected in Cell-free Circulating Tumor DNA (ctDNA) Prior to CDK4/6 Inhibitor (CDK4/6i) Plus Endocrine Therapy (ET) Treatment
8:00 am: Hall A and On Demand
Seth Wander, MD, PhD; Aditya Bardia, MD, MPH

Exploratory Biomarker Analysis of acelERA Breast Cancer (BC): Phase II Study of Giredestrant vs. Physician’s Choice of Endocrine Therapy (PCET) for Previously Treated, Estrogen Receptor-positive, HER2-negative Advanced BC (ER+, HER2– aBC)
8:00 am: Hall A and On Demand
Aditya Bardia, MD, MPH

Neoadjuvant HER2-targeted Therapy +/- Immunotherapy With Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial
8:00 am: Hall A and On Demand
Laura Spring, MD; Aditya Bardia, MD, MPH

Endocrine Therapy Resistance (ETR) in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer (HR+, HER2– mBC): Prevalence, Biomarker Characteristics, and Outcomes
8:00 am: Hall A and On Demand
Seth Wander, MD, PhD

lidERA Breast Cancer (BC): Phase III Adjuvant Study of Giredestrant vs. Physician’s Choice of Endocrine Therapy (PCET) in Patients (pts) With Estrogen Receptor-positive, HER2-negative Early BC (ER+, HER2– eBC)
8:00 am: Hall A and On Demand
Aditya Bardia, MD, MPH

Alpelisib + Endocrine Therapy in Patients With PIK3CA-mutated, Hormone Receptor–positive, Human Epidermal Growth Factor Receptor 2–negative, Advanced Breast Cancer: Analysis of All 3 Cohorts of the BYLieve Study
8:00 am: Hall A and On Demand
Dejan Juric, MD

Neoadjuvant Giredestrant + Palbociclib (P) vs. Anastrozole (A) + P in Postmenopausal Women With Estrogen Receptor-positive, HER2-negative, Untreated Early Breast Cancer (ER+, HER2– eBC): Patient (pt)-reported Outcomes (PROs) in the Randomized, Open-label, International Phase II coopERA BC Study
8:00 am: Hall A and On Demand
Aditya Bardia, MD, MPH

State-of-the-Art Management of HER2-negative Early Breast Cancer: Treatment Patterns Among Healthcare Professionals and Concordance With Expert Recommendations
8:00 am: Hall A and On Demand
Laura Spring, MD

Sequential Use of Antibody-drug Conjugate After Antibody-drug Conjugate for Patients With Metastatic Breast Cancer: ADC After ADC (A3) Study
11:00 am: Hall D2 and Livestream
Rachel Occhiogrosso Abelman, MD; Laura Spring, MD; Neelima Vidula, MD; Arielle Medford, MD; Jennifer Shin, MD; Seth Wander, MD, PhD; Steven Isakoff, MD, PhD; Beverly Moy, MD, MPH; Leif Ellisen, MD, MPH; Aditya Bardia, MD, MPH

Interim Update of the ATRC-101 Phase 1b Trial in Advanced Solid Tumors
11:29 am: Hall A and On Demand
Steven Isakoff, MD, PhD

Intracranial and Systemic Efficacy of Repotrectinib in Advanced ROS1 Fusion-positive (ROS1+) Non-small Cell Lung Cancer (NSCLC) and Central Nervous System Metastases (CNS mets) in the Phase 1/2 TRIDENT-1
4:42 pm: Hall D1
Jessica Jiyeong Lin, MD

Monday, June 5, 2023

A Phase II Study of Nivolumab and Ipilimumab With Radiation Therapy in Patients With Metastatic, Microsatellite Stable Colorectal Cancer
8:00 am: Hall A and On Demand
Julie L. Koenig, MD; Jeffrey Clark, MD; Samuel Klempner, MD; David Ryan, MD; Jill Allen, MD; Lawrence Blaszkowsky, MD; Theodore Hong, MD; Aparna Parikh, MD; Lorraine Drapek, DNP FNP-BC AOCNP; Bruce Giantonio, MD

Efficacy and Safety of Elranatamab by Age and Frailty in Patients (pts) With Relapsed/Refractory Multiple (RRMM): A Subgroup Analysis From MagnetisMM-3
8:00 am
Noopur S. Raje, MD

Rates of Cytokine Release Syndrome (CRS) and Immune Effector Cell–associated Neurotoxicity Syndrome (ICANS) From Center for International Blood and Marrow Transplant Research (CIBMTR) Data on US Subjects (SUBJ) With Lymphoma Following Chimeric Antigen Receptor T Cell Therapy (CAR-T)
8:00 am: Hall A and On Demand
Matthew J. Frigault, MD

Uncertainty and Coping in Patients With Newly Diagnosed Indolent Non-Hodgkin’s Lymphoma (iNHL)
8:00 am: Hall A and On Demand
Richard Newcomb, MD, BA

Advancing Individualized Care in Advanced Gastroesophageal Cancers (GEC): A Quality Improvement Initiative
8:00 am: Hall A and On Demand
Matthew Strickland, MD

STAR-221: A Randomized, Open-label, Multicenter, Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Previously Untreated, Locally Advanced, Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
8:00 am: Hall A and On Demand
Samuel Klempner, MD

Circulating Tumor DNA as a Marker of Recurrence Risk in Locoregional Esophagogastric Cancers With Pathologic Complete Response
8:00 am: Hall A
Samuel Klempner, MD

Telehealth-based Psychological Intervention for Caregivers of Patients With Primary Malignant Brain Tumors: A Randomized Controlled Trial
10:24 am: S100a and Livestream
Deborah Forst, MD

Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–positive/HER2-negative (HR+/HER2–) Metastatic Breast Cancer (mBC)
12:30 pm: Hall B1 and Livestream
Aditya Bardia, MD, MPH

Dynamic HER2-low Status Among Patients With Triple Negative Breast Cancer (TNBC): The Impact of Repeat Biopsies
12:54 pm: Hall B1 and Livestream
Yael Bar, MD, PhD; Aditya Bardia, MD, MPH; Beverly Moy, MD, MPH; Leif Ellisen, MD, PhD; Steven Isakoff, MD, PhD

The Influence of Sex on the Impact of Age and Frailty on Acute Care Use Among Older Adults Receiving Immune Checkpoint Inhibitor (ICI) Treatment: A Population-based Study
1:15 pm: Hall A and On Demand
Jeffrey Peppercorn, MD, MPH

Smoking Cessation Support and Knowledge Among Newly Diagnosed Individuals at Community Cancer Centers (ECOG-ACRIN Trial EAQ171CD)
1:15 pm: Hall A and On Demand
Elyse Park, PhD

Race and Ethnicity Reporting by US Federal Standards in High-impact Phase 2/3 Oncology Clinical Trial Publications
1:15 pm: Hall A and On Demand
Jeffrey Peppercorn, MD, MPH

Patient-reported Hope, Prognostic Understanding, Quality of Life, Symptom Burden, Coping Mechanisms, and Financial Wellbeing in Early Phase Clinical Trial Participants
1:15 pm: Hall A and On Demand
Debra Lundquist, PhD, RN; Sienna Durbin, MD; Casandra McIntyre, RN; Dejan Juric, MD; Betty Ferrell, PhD; Rachel Jimenez, MD; Ryan Nipp, MD, MPH

Facilitating the Transition to Posttreatment Survivorship for Adolescent and Young Adults: A Randomized Waitlist Control Trial of a Virtual Mind-body Intervention
1:15 pm: Hall A and On Demand
Giselle Katiria Perez, PhD; Joseph Greer, PhD; Jeffrey Peppercorn, MD, MPH; Elyse Park, PhD

Associations Among Anesthesia-induced Brain Biomarkers During Surgery, Preoperative Exposure to Cancer Therapeutics, and Clinical Outcomes
1:15 pm: Hall A and On Demand
Tom A.D. Stone, ScM

Association Between Inpatient Clinical Nursing Acuity and 30-day Rehospitalization Among Hospitalized Patients With Advanced Cancer
1:15 pm: Hall A and On Demand
Daniel Lage, MD, MSc

The Effect of Maintenance Hormone Therapy on Overall Survival in Advanced-Stage Low-grade Serous Ovarian Carcinoma: A Risk-set Matched Retrospective Study
1:15 pm: Hall A and On Demand
Syem Barakzai, MD

Mechanisms of Resistance to Bispecific T-cell Engager Therapy for Ovarian Cancer
1:15 pm: Hall A and On Demand
Syem Barakzai, MD

Trends in the Use of Neoadjuvant Chemotherapy for Low-grade Serous Ovarian Cancer in the United States
1:15 pm: Hall A and On Demand
Jason Silberman, MD; Amy Bregar, MD

A Phase 2, Two-stage Study of Avelumab and Axitinib in Patients With Mismatch Repair–Proficient (MMR-P) Recurrent or Persistent Endometrial Cancer (EC)
1:15 pm: Hall A and On Demand
Oladapo Yeku, MD, PhD, FACP; Cesar Castro, MD; Richard Penson, MBBS

Falls and Hospitalization During Chemotherapy in Older Women With Early Breast Cancer
1:15 pm: Hall A and On Demand
Beverly Moy, MD, MPH

Adjuvant Endocrine Therapy Adherence Changes Among Patients After a Virtual Behavioral Intervention
1:15 pm: Hall A and On Demand
Jamie Jacobs, PhD; Jeffrey Peppercorn, MD, MPH; Elyse Park, PhD; Jennifer Temel, MD; Joseph Greer, PhD

ctDNA in the Management of Early Colorectal Cancer: The Time Has Come!
3:00 pm: Hall D2
Aparna Parikh, MD

Clinical and Immune Phenotypes Associated With Immune Checkpoint Inhibitor-induced Autoimmune Diabetes
3:00 pm: S406 and On Demand
Karina Nicole Ruiz-Esteves, MD; Alexandra Chloé Villani, PhD; Kerry L. Reynolds, MD

Developing Machine Learning Algorithms Incorporating Patient Reported Outcome Measures to Predict Acute Care Events Among Patients With Cancer
4:30 pm: S102 and On Demand
Thomas J. Roberts, MD, MBA; Jennifer Temel, MD; Joseph Greer, PhD; Therese Mulvey, MD

Managing the Lows of Cancer Treatment
5:36 pm: S404 and On Demand
Ryan Nipp, MD, MPH

Tuesday, June 6, 2023

Sharpening Our Tools: The Next Wave of Early Detection Technologies
8:30 am: E451 and On Demand
Lecia V. Sequist, MD, MPH